the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient (IDBUCY)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study was a multi-center, open, randomized-control study on the effects and safety of idarubicin 60mg/M2 combined with BUCY pretreatment program or BUCY pretreatment program on the overall survival rate and disease-free survival rate of acute myeloid leukemia patient in high-risk group over a period of 2 years.
| Condition | Intervention | Phase |
|---|---|---|
|
Acute Myeloid Leukemia |
Drug: Cyclosporin A,mycophenolate mofetil,Methotrexate |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Multi-center, Open, Randomized-control Study to Compare the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient |
- 2-year disease-free survival (DFS) rates [ Time Frame: 4 years ] [ Designated as safety issue: No ]The purpose of this study is to evaluates the effects of idarubicin 60mg/M2 combined with BUCY pretreatment program or BUCY pretreatment program on acute myeloid leukemia patient in high-risk group.
- 2-year overall survival (OS) rates [ Time Frame: 4 years ] [ Designated as safety issue: No ]It evaluates the effects of idarubicin 60mg/M2 combined with BUCY pretreatment program or BUCY pretreatment program on acute myeloid leukemia patient in high-risk group. 200 patients were studied with 100 patients in each group
- safety of idarubicin 60mg/M2 combined with BUCY pretreatment program or BUCY pretreatment program [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]safety evaluation (early complications of transplantation, liver, kidney and heart toxicity, treatment-related mortality, blood recovery time),
| Estimated Enrollment: | 200 |
| Study Start Date: | August 2012 |
| Estimated Study Completion Date: | June 2016 |
| Estimated Primary Completion Date: | January 2016 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: IDBUCY
Idarubicin: 20mg/m2 a day, d-12 ~d-10, intravenous infusion for 1 hour. Busulfan: 4mg/Kg a day, oral administration, d-7 ~d-4, or 3.2mg/Kg a day, intravenous infusion, d-7~d-4. cyclophosphamide: 60mg/Kg a day, intravenous infusion, d-3~d-2. |
Drug: Cyclosporin A,mycophenolate mofetil,Methotrexate
GVHD is prevented by CSA+MMF+MTX in sibling allogeneic hematopoietic stem cell transplantation (starting from day -1, 3mg/kg of CSA was infused by continuous intravenous drip until gastrointestinal function returned normal when method of administration was changed to oral administration.
|
|
Active Comparator: BUCY
Busulfan: 4mg/Kg a day, oral administration, d-7 ~d-4, or 3.2mg/Kg a day, intravenous infusion, d-7~d-4. Cyclophosphamide: 60mg/Kg a day, intravenous infusion, d-3~d-2. |
Drug: Cyclosporin A,mycophenolate mofetil,Methotrexate
GVHD is prevented by CSA+MMF+MTX in sibling allogeneic hematopoietic stem cell transplantation (starting from day -1, 3mg/kg of CSA was infused by continuous intravenous drip until gastrointestinal function returned normal when method of administration was changed to oral administration.
|
Detailed Description:
This study was a multi-center, open, randomized-control study. It evaluates the effects and safety of idarubicin 60mg/M2 combined with BUCY pretreatment program or BUCY pretreatment program on acute myeloid leukemia patient in high-risk group. 200 patients were studied with 100 patients in each group.
Patients enrolled were randomly divided into group A (idarubicin 60mg/M2 combined with BUCY group) and group B (BUCY group). SAS randomization software was used to obtain randomization numbers. Patients were recommend to start pretreatment within 7 days after randomization.
Main objective: 2-year overall survival (OS) and disease-free survival (DFS) rates.
Secondary objective: safety evaluation (early complications of transplantation, liver, kidney and heart toxicity, treatment-related mortality, blood recovery time), the median period of disease-free survival.
Test drugs Idarubicin (Zavedos ®, Pfizer), busulfan, cyclophosphamide.
Pretreatment plan Drug Group A (IDA 60mg/M2 + BUCY) Group B (BUCY) IDA: 20mg/m2 a day, d-12 ~d-10, intravenous infusion for 1 hour. BU: 4mg/Kg a day, oral administration, d-7 ~d-4, or 3.2mg/Kg a day, intravenous infusion, d-7~d-4.
CY: 60mg/Kg a day, intravenous infusion, d-3~d-2. GVHD prevention plan GVHD is prevented by CSA+MMF+MTX in sibling allogeneic hematopoietic stem cell transplantation (starting from day -1, 3mg/kg of CSA was infused by continuous intravenous drip until gastrointestinal function returned normal when method of administration was changed to oral administration. 5mg/kg was divided into twice oral intakes, maintaining cyclosporine concentration at 200-300ug / L; MTX 15mg/m2 at day +1, 10mg/m2 at day +3, +6 and day +11 (based on actual situations day 11 can be omitted); MMF 0.25g BID starting from day 0 and continued for a month ). Unrelated allogeneic hematopoietic stem cell transplantation used CSA MMF MTX ATG for the prevention of GVHD. 3mg/kg CSA was infused through continuous intravenous drip since day -1 until gastrointestinal function returned to normal when the administration method was changed to oral. 5mg/kg was divided to twice oral intakes maintaining cyclosporine concentrations at 200-300ug/L; MTX 15mg/m2, at day +1, 10mg/m2 at day +3, day +6 and day +11 (based on actual situations day 11 can be omitted); MMF 0.5g BID starting from day 0 and continued for 3 months (a month later, dose can be reduced according to the hemogram); the total ATG was 6mg/kg and was taken in three days, from day -4 to day -2.
Relapse intervention Routine preventive DLI is not recommended, however, if tendency of recurrence found during monitor, chemotherapy, immunotherapy, targeted therapy, secondary transplantation, etc. can be used, and intervention treatment start time should be recorded as the end time.
The efficacy evaluation time point
- 1-3, 6, 12, 18, 24 months after transplantation.
- Follow-up evaluation: indicators such as blood routines and bone marrow detection, and minimal residual disease detection after the end of treatment should be done regularly.
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age: 18～50;
- Received peripheral blood hematopoietic stem cell transplantation from siblings or unrelated allogeneic donors with identical matching of HLA or 1 alleles mismatched.
- Diagnosis: refer to 2011 edition of AML China Guideline for the diagnosis and treatment and diagnosis standards of high-risk acute myeloid leukemia developed through literatures (see Appendix B);
- Under general condition, ECOG score ≤ 1;
- Normal cardiac functions;
- Normal liver and renal function: blood bilirubin≤35 μ mol\/L, AST/ALT lower than twice in the upper limit of normal value, serum creatinine≤ 150 μ mol\/L;
- Subjects have signed the informed consent form.
Exclusion Criteria:
- Severe uncontrolled infection before transplantation;
- With contraindications of idarubicin;
- Reached the maximum cumulative dose of anthracyclines, for instance, DNR≥ 450mg/m2, mitoxantrone≥140mg/m2, the total cumulative dose of idarubicin≥ 300mg/m2;
- The other conditions that do not meet the inclusion criteria.
Withdrawal criteria:
- Those do not meet the inclusion criteria or meet the exclusion criteria after reviewing;
- Patient withdraws the informed consent form;
- Patient violates the clinical study protocol;
- Patient experiences severe adverse events that treatment has to be terminated;
- Patient that considered no longer fit to complete clinical trials by researchers.
Contacts and Locations| Contact: Lai Yongrong, doctor | 0086-13517711828 | laiyongrong@263.net |
| Contact: Li Qiaochuan, doctor | 0086-13768411929 | liqiaochuan@sohu.com |
| China, Guangxi | |
| First Affiliated Hospital of Guangxi Medical University | Recruiting |
| Nanning, Guangxi, China, 530021 | |
| Contact: Lai Yongrong, doctor 0086-13517711828 laiyongrong@263.net | |
| Contact: Zhang Zhongming, doctor 0086-15807801369 zzmmissyou@126.com | |
| Principal Investigator: Lai Yongrong, doctor | |
| Sub-Investigator: Zhang Zhongming, doctor | |
| Sub-Investigator: Li Qiaochuan, doctor | |
More Information
Additional Information:
No publications provided
| Responsible Party: | Lan YongRong, Director of the Hematology department of the First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University |
| ClinicalTrials.gov Identifier: | NCT01766375 History of Changes |
| Other Study ID Numbers: | GuangXi-AML- HSCT-2012-07 |
| Study First Received: | December 28, 2012 |
| Last Updated: | January 9, 2013 |
| Health Authority: | China:The First Affiliated Hospital of Guangxi Medical University China:Shanghai Ruijin Hospital China:Guangdong Provincial People's Hospital China:Wuhan Tongji Hospital China:Yunnan Military Hospital China:The First People's Hospital of Shanghai China:The First Affiliated Hospital of Chongqing Medical University China:Affiliated Hospital of Guiyang Medical College China:The First Affiliated Hospital of Xinjiang Medical College China:The First People's Hospital of Yunnan Province China:The First Affiliated Hospital of Anhui Medical University China:Tang Du Hospital of Fourth Military Medical University China:The First Affiliated Hospital of Nanchang University China:Henan Cancer Hospital |
Keywords provided by Guangxi Medical University:
|
idarubicin busulfan cyclophosphamide pretreatment high-risk acute myeloid leukemia patient |
Additional relevant MeSH terms:
|
Leukemia Leukemia, Myeloid, Acute Leukemia, Myeloid Neoplasms by Histologic Type Neoplasms Busulfan Cyclophosphamide Cyclosporins Cyclosporine Methotrexate Mycophenolate mofetil Idarubicin Mycophenolic Acid Immunosuppressive Agents Immunologic Factors |
Physiological Effects of Drugs Pharmacologic Actions Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Therapeutic Uses Myeloablative Agonists Antirheumatic Agents Enzyme Inhibitors Antifungal Agents Anti-Infective Agents Dermatologic Agents Antibiotics, Antineoplastic Abortifacient Agents, Nonsteroidal |
ClinicalTrials.gov processed this record on May 23, 2013